Literature DB >> 33543229

Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers.

Yomna S Abd El-Aziz1,2,3, Andrew J Spillane4,5, Patric J Jansson1,2,6, Sumit Sahni1,2.   

Abstract

Triple-negative breast cancer (TNBC) is a group of breast cancers which neither express hormonal receptors nor human epidermal growth factor receptor. Hence, there is a lack of currently known targeted therapies and the only available line of systemic treatment option is chemotherapy or more recently immune therapy. However, in patients with relapsed disease after adjuvant or neoadjuvant therapy, resistance to chemotherapeutic agents has often developed, which results in poor treatment response. Multidrug resistance (MDR) has emerged as an important mechanism by which TNBCs mediate drug resistance and occurs primarily due to overexpression of ATP-binding cassette (ABC) transporter proteins such as P-glycoprotein (Pgp). Pgp overexpression had been linked to poor outcome, reduced survival rates and chemoresistance in patients. The aim of this mini-review is to provide a topical overview of the recent studies and to generate further interest in this critical research area, with the aim to develop an effective and safe approach for overcoming Pgp-mediated chemoresistance in TNBC.
© 2021 The Author(s).

Entities:  

Keywords:  breast cancers; multidrug resistance; p-glycoprotein; triple negative breast cancer

Mesh:

Substances:

Year:  2021        PMID: 33543229      PMCID: PMC7909869          DOI: 10.1042/BSR20204092

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


  84 in total

1.  Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp).

Authors:  Patric J Jansson; Tetsuo Yamagishi; Akanksha Arvind; Nicole Seebacher; Elaine Gutierrez; Alexandra Stacy; Sanaz Maleki; Danae Sharp; Sumit Sahni; Des R Richardson
Journal:  J Biol Chem       Date:  2015-02-26       Impact factor: 5.157

2.  Establishment and characterization of a triple negative basal-like breast cancer cell line with multi-drug resistance.

Authors:  Sergei Boichuk; Aigul Galembikova; Alexandr Sitenkov; Ramil Khusnutdinov; Pavel Dunaev; Elena Valeeva; Natalia Usolova
Journal:  Oncol Lett       Date:  2017-08-23       Impact factor: 2.967

3.  Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.

Authors:  C Cordon-Cardo; J P O'Brien; D Casals; L Rittman-Grauer; J L Biedler; M R Melamed; J R Bertino
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

4.  Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration.

Authors:  A Stewart; J Steiner; G Mellows; B Laguda; D Norris; P Bevan
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

Review 5.  Molecular pathways: regulation and therapeutic implications of multidrug resistance.

Authors:  Kevin G Chen; Branimir I Sikic
Journal:  Clin Cancer Res       Date:  2012-02-16       Impact factor: 12.531

Review 6.  Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.

Authors:  Roel H Wilting; Jan-Hermen Dannenberg
Journal:  Drug Resist Updat       Date:  2012-02-20       Impact factor: 18.500

7.  Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.

Authors:  E B Mechetner; I B Roninson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

8.  Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy.

Authors:  Margaretha Rudas; Martin Filipits; Susanne Taucher; Thomas Stranzl; Günther G Steger; Raimund Jakesz; Robert Pirker; Gudrun Pohl
Journal:  Breast Cancer Res Treat       Date:  2003-09       Impact factor: 4.872

9.  Subcellular localization and activity of multidrug resistance proteins.

Authors:  Asha Rajagopal; Sanford M Simon
Journal:  Mol Biol Cell       Date:  2003-04-17       Impact factor: 4.138

10.  Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration.

Authors:  B Chapuy; R Koch; U Radunski; S Corsham; N Cheong; N Inagaki; N Ban; D Wenzel; D Reinhardt; A Zapf; S Schweyer; F Kosari; W Klapper; L Truemper; G G Wulf
Journal:  Leukemia       Date:  2008-05-08       Impact factor: 11.528

View more
  1 in total

1.  A comparative study of the ability of recombinant oncolytic adenovirus, doxorubicin and tamoxifen to inhibit the proliferation of breast cancer cells.

Authors:  Shanzhi Li; Zhuoxin Li; Yiquan Li; Yilong Zhu; Jicheng Han; Wenjie Li; Ningyi Jin; Jinbo Fang; Xiao Li; Guangze Zhu
Journal:  J Cell Mol Med       Date:  2022-09-23       Impact factor: 5.295

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.